SCHA vs XBI

Schwab US Small-Cap ETF vs SPDR S&P Biotech ETF

Quick take
  • • SCHA has the lower expense ratio at 0.03% vs 0.35% for XBI.
  • • SCHA pays a higher dividend yield (1.12%).

Side-by-side metrics

MetricSCHAXBI
Expense ratio
Annual fee. Lower is better.
0.03%0.35%
Dividend yield
Trailing 12-month yield.
1.12%0.35%
AUM
Assets under management — bigger funds are typically more liquid.
$22.04B$10.92B
YTD return
18.09%28.80%
1-year return
——
3-year return
Annualized.
——
5-year return
Annualized.
——
10-year return
Annualized.
——
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
1.231.01
P/E ratio
16.37—
Last price
$33.55$156.41
Inception
——
Issuer
SchwabState Street

SCHA top holdings

Top holdings · SCHA
HALOHalozyme Therapeutics Inc0.36%
GKOSGlaukos Corp0.34%
WWayfair Inc Class A0.32%
BMNRBitMine Immersion Technologies Inc0.29%
AHRAmerican Healthcare REIT Inc Ordinary Shares0.28%
BTSGBrightSpring Health Services Inc0.27%
RRyder System Inc0.26%
VSATViasat Inc0.26%
ENSGEnsign Group Inc0.25%
WTFCWintrust Financial Corp0.25%
Sector breakdown · SCHA
Real Estate6.9%
Consumer Cyclical11.1%
Basic Materials4.2%
Consumer Defensive2.9%
Technology15.1%
Communication Services2.8%
Financial Services16.9%
Utilities2.5%
Industrials14.5%
Energy5.8%
Healthcare17.3%

XBI top holdings

Top holdings · XBI
MRNAModerna Inc2.37%
NTRANatera Inc1.82%
HALOHalozyme Therapeutics Inc1.77%
TWSTTwist Bioscience Corp1.77%
BIIBBiogen Inc1.75%
AMGNAmgen Inc1.73%
EXELExelixis Inc1.73%
UTHRUnited Therapeutics Corp1.72%
ABBVAbbVie Inc1.71%
GILDGilead Sciences Inc1.70%
Sector breakdown · XBI
Financial Services0.6%
Healthcare99.3%

About SCHA

SCHA (Schwab US Small-Cap ETF) is US small-cap equities. Managed by Schwab, the fund carries $22.0B in assets under management, an expense ratio of 0.03%, a dividend yield of 1.12%. Its largest holding is Halozyme Therapeutics Inc (HALO), which represents 0.4% of the portfolio. Real Estate is the fund's largest sector exposure at 6.9%.

About XBI

XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.